Real‐world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus

Abstract Aims Tirzepatide is a first‐in‐class combination glucose‐dependent insulinotropic polypeptide (GIP) receptor agonist and glucagon‐like peptide 1 receptor agonist (GLP1‐RA) approved for treatment of adults with type 2 diabetes mellitus (T2DM) and chronic weight management. The aim of this analysis was to assess the real‐world efficacy of tirzepatide in patients with T2DM. Methods This retrospective observational study evaluated patients with T2DM from a large urban academic medical centre who received at least 3 months of continuous tirzepatide treatment. The primary outcome was change in A1C from following tirzepatide treatment. Secondary outcomes included change in body weight and body mass index (BMI) after tirzepatide was initiated. Results A total of 1896 patient charts were reviewed, and 612 patients were evaluated for the primary outcome. Over a median time period of 10.4 months, treatment with tirzepatide resulted in a mean A1C reduction of 1.02 ± 1.48% ( p < 0.001). A total of 570 patients were evaluated for the secondary outcomes. Tirzepatide was associated with a mean reduction in body weight of 7.3 ± 9.3 kg ( p < 0.001) and a mean reduction in BMI of 2.5 kg/m 2 . Greater A1C lowering and weight loss was observed in patients without prior GLP1‐RA treatment compared to those switched to tirzepatide from GLP1‐RA. Conclusions In a real‐world population of US patients with T2DM, tirzepatide was associated with clinically and statistically significant reductions in A1C and body weight. Greater reductions in both A1C and body weight were observed among patients who were GLP1‐RA naïve compared to patients switched from GLP1‐RA to tirzepatide.